Drug profile · INN
pasireotide diaspartate
SIGNIFOR
pasireotide diaspartate (SIGNIFOR) is a somatostatin receptor 2 agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — pasireotide diaspartate
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
pasireotide diaspartate (SIGNIFOR) is a somatostatin receptor 2 agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Somatostatin receptor 2 agonist
Primary target: Somatostatin receptor type 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is pasireotide diaspartate?
pasireotide diaspartate (SIGNIFOR) is a somatostatin receptor 2 agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for pasireotide diaspartate?
SIGNIFOR is a marketed brand name for pasireotide diaspartate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pasireotide diaspartate?
pasireotide diaspartate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.